Identification of a potential prognostic plasma biomarker of acute ischemic stroke via untargeted LC-MS metabolomics.

IF 2.1 4区生物学 Q3 BIOCHEMICAL RESEARCH METHODS

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-06-27 DOI:10.1002/prca.202200081

Ming-Hsiu Wu, Chiz-Tzung Chang, Yu-Ning Lin, Chao-Jung Chen

{"title":"Identification of a potential prognostic plasma biomarker of acute ischemic stroke via untargeted LC-MS metabolomics.","authors":"Ming-Hsiu Wu, Chiz-Tzung Chang, Yu-Ning Lin, Chao-Jung Chen","doi":"10.1002/prca.202200081","DOIUrl":null,"url":null,"abstract":"Purpose: Stroke is the sudden death of brain cells in a localized area due to an inadequate blood flow or blood vessel rupture, and it seriously affects the quality of life. The metabolite biomarkers are needed for predicting the functional outcome of acute ischemic stroke (AIS).Experimental design: To identify biomarkers for AIS, untargeted LC/MS metabolomics was performed on plasma samples from subjects with favorable prognosis (mRS ≤ 2) and unfavorable prognosis (mRS > 2). The identified markers were further absolutely quantified by a targeted MRM approach.Results: There were 10 upregulated and 26 downregulated markers. Among these candidates, one was successfully identified as glycocholic acid and then absolutely quantified in plasma samples. Glycocholic acid could discriminate between subjects with favorable and unfavorable prognosis with an area under the curve (AUC) of 0.68 and odds ratio of 5.88.Conclusions and clinical relevance: Glycocholic acid was identified as a potential plasma metabolite marker of non-progressive outcomes after ischemic stroke and could serve as predictive prognostic markers for clinical acute stroke outcomes.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2200081"},"PeriodicalIF":2.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.202200081","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose: Stroke is the sudden death of brain cells in a localized area due to an inadequate blood flow or blood vessel rupture, and it seriously affects the quality of life. The metabolite biomarkers are needed for predicting the functional outcome of acute ischemic stroke (AIS).

Experimental design: To identify biomarkers for AIS, untargeted LC/MS metabolomics was performed on plasma samples from subjects with favorable prognosis (mRS ≤ 2) and unfavorable prognosis (mRS > 2). The identified markers were further absolutely quantified by a targeted MRM approach.

Results: There were 10 upregulated and 26 downregulated markers. Among these candidates, one was successfully identified as glycocholic acid and then absolutely quantified in plasma samples. Glycocholic acid could discriminate between subjects with favorable and unfavorable prognosis with an area under the curve (AUC) of 0.68 and odds ratio of 5.88.

Conclusions and clinical relevance: Glycocholic acid was identified as a potential plasma metabolite marker of non-progressive outcomes after ischemic stroke and could serve as predictive prognostic markers for clinical acute stroke outcomes.

查看原文本刊更多论文

通过非靶向LC-MS代谢组学鉴定急性缺血性卒中潜在预后血浆生物标志物。

目的:中风是由于血流不足或血管破裂导致局部脑细胞突然死亡，严重影响生活质量。代谢物生物标志物是预测急性缺血性卒中(AIS)功能结局所必需的。实验设计:为了鉴定AIS的生物标志物，我们对预后良好(mRS≤2)和预后不良(mRS > 2)受试者的血浆样本进行了非靶向LC/MS代谢组学研究，并通过靶向MRM方法对鉴定出的标志物进行绝对定量。结果:上调10个，下调26个。在这些候选物中，有一种被成功地鉴定为糖胆酸，然后在血浆样品中绝对定量。糖胆酸能区分预后好坏，曲线下面积(AUC)为0.68，优势比为5.88。结论和临床意义:糖胆酸被确定为缺血性卒中后非进展性结局的潜在血浆代谢物标志物，并可作为临床急性卒中结局的预测预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PROTEOMICS – Clinical Applications 医学-生化研究方法

CiteScore

5.20

自引率

5.00%

发文量

审稿时长

1 months

期刊介绍： PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.